Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 8/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 4/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4799542 | 1.00 | IDH1 (0.50) | IDH1HSD17B3PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6387449 | 0.91 | HSD17B3 (0.56) | IDH1HSD17B3USP30 | |
| SCHEMBL6387452 | 0.91 | HSD17B3 (0.56) | IDH1HSD17B3USP30 | |
| SCHEMBL4796570 | 0.89 | HSD17B3 (0.47) | IDH1HSD17B3USP30 | |
| SCHEMBL4796559 | 0.89 | HSD17B3 (0.47) | IDH1HSD17B3USP30 | |
| Trifluoroacetic Acid SCHEMBL4796891 | 0.85 | HSD17B3 (0.50) | IDH1HSD17B3USP30 | |
| SCHEMBL4054562 | 0.82 | HSD17B3 (0.55) | HSD17B3USP30 | |
| SCHEMBL4054560 | 0.82 | HSD17B3 (0.55) | HSD17B3USP30 | |
| SCHEMBL4231743 | 0.80 | ALPL (0.39) | HSD17B3KDR | |
| SCHEMBL5038877 | 0.80 | HSD17B3 (0.53) | HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B11, HSD17B1 | IDH1 135/4885HSD17B3 1/4885PIK3CD 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.